Clinical Trial Update: First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Daiichi Sankyo's DS-2243a is entering first-in-human evaluation in a Phase 1 study for adults with advanced solid tumors, and the trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sarcoma

Drugs mentioned

• DS-2243a

Snippet

Sponsor: Daiichi Sankyo | Conditions: Solid Tumors, Sarcoma | Phase 1 | Status: RECRUITING